9th Congress of the Andalucian Transplantation SocietyKidney transplantationIncidence and Long-Term Prognosis of Cancer After Kidney Transplantation
Section snippets
Selection and Description of Participants
We retrospectively analyzed the development of de novo cancers among our population of kidney transplants recipients from January 1979 to January 2015. All transplanted patients were followed at our outpatient care unit as long as their transplanted kidney functioned. In case of complication, they were admitted to our department. Patient data and posttransplantation complications were registered in our database. Transplanted patients received triple immunosuppressive therapy with
Patient Characteristics and Clinical Variables
There were 1450 renal transplantations performed in our hospital between January 1979 and January 2015 (1424 from deceased donors and 26 from living donors). A total of 178 were combined transplants (164/178 pancreas–kidney transplantation). The mean follow-up was 10 years.
We studied 194 transplanted patients who developed SOC, PTLD, or NMSC. Most transplant patients with cancer were male (74%) and showed a mean age at presentation of 59 ± 10 years. Patient's demographics and clinical
Discussion
The problem of de novo tumors developing after kidney transplantation is progressively growing. It is owing to increased age of the transplanted population and the long-term immunosuppressive therapy [15], [16], [17]. In addition, malignancy represents an important cause of mortality after renal transplantation; it is the third leading cause of death in Spain and the United States, and the second leading cause in Australia [18].
In our study, we analyzed a kidney transplant cohort of 194
References (18)
- et al.
Cancer after kidney transplantation in the United States
Am J Transplant
(2004) - et al.
Cancer incidence and survival in kidney transplant patients
Transplant Proc
(2008) - et al.
Malignancy-related mortality following kidney transplantation is common
Kidney Int
(2014) - et al.
Cancer risk in patients on dialysis and after renal transplantation
Lancet
(2000) - et al.
De novo malignancies after kidney transplantation
Urology
(2007) - et al.
Evaluation of posttransplantation malignancies compared with de novo tumors
Transplant Proc
(2007) - et al.
Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation
Crit Rev Oncol Hematol
(2005) - et al.
De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases
Transplant Proc
(2006) - et al.
Skin cancer and immunosuppression
Crit Rev Oncol Hematol
(2005)
Cited by (23)
Everolimus Use in Lung Transplant Recipients
2022, Transplantation ProceedingsEarly Complications After Kidney Transplantation in Patients Aged 60 Years and Older: A Single-Center, Paired-Kidney Analysis
2020, Transplantation ProceedingsDe Novo Cancer Incidence and Prognosis After Kidney Transplantation: A Single Center Analysis
2019, Transplantation ProceedingsCitation Excerpt :Prognosis in kidney transplant recipients developing a de novo post-transplant cancer is poorly investigated. In a recent study, Pendón-Ruiz de Mier et al [12] reported that the mean survival time from the diagnosis of cancer was 2.09 years, whereas in a previous study the same group [11] reported similar graft and patient survival among kidney-transplant recipients developing a cancer after transplantation compared with recipients without cancer. More recently, Benoni et al [10] demonstrated that kidney transplant recipients with a post-transplant cancer had a worse survival compared with nontransplant patients with cancer.
Prevalence and Survival of Cancer After Pancreas-Kidney Transplantation
2018, Transplantation ProceedingsCitation Excerpt :From 194 PKTs, we analyzed a cohort of 12 patients who developed NSOM. Compared with our kidney transplant recipients, the prevalence of NSOM was lower: 6.1% in PKT versus 7.4% in kidney transplantation [5]. Despite a higher level of immunosuppressive therapy, PKT was not associated with an increased rate of post-transplant malignancies compared with kidney transplantation alone.
Etiology (Risk Factors for Bladder Cancer)
2018, Bladder CancerModification of immunosuppressive therapy as risk factor for complications after liver transplantation
2017, Best Practice and Research: Clinical Gastroenterology